Protagonist Therapeutics

PTGX | NASDAQ | 0 Urmăritori

$50.69

+0.96%

$0.48

Urmărește

Overview Metrics Financials

Fair Price

$29.84

Overvalued by 11.2%

Pentru a afișa prețul corect al unei acțiuni, trebuie să fiți membru Bulios Black.

Profile

Protagonist Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing peptide-based therapeutics for hematological disorders and inflammatory diseases. Their lead candidate, rusfertide, is a synthetic mimetic of the hormone hepcidin, currently in Phase 3 clinical trials for the treatment of polycythemia vera, a rare blood disorder. In 2024, the company entered into an agreement with Takeda Pharmaceutical, receiving an upfront payment of $300 million for global commercialization rights to rusfertide outside the U.S.

Feed

There are no posts to show right now.

Protagonist Therapeutics

Fair Price

Profile

Feed

Logare în Bulios

Creează-ți profilul pe Bulios

De ce Bulios?